Search
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Products: XADAGO 50 MG TABLETAS RECUBIERTAS CON PELÍCULA, Equfina Film coated Tablets 50 mgPrimidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.
Products: MYSOLINE TABLETAS, PRIMIDONA 250 MG TABLETASCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acidProducts: CEPRAX CAPSULAS DE 500 MG, CEPRAX® CAPSULAS DE 500 MGNaratriptan
go.drugbank.com/drugs/DB00952ApprovedNaratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Synonyms: N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamideProducts: NARAMIG TABLETAS 2.5 MG, NARAMIG TABLETS 2.5 mgEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663] … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.
Mixtures: FORECOX-TRAC TABLETAS RECUBIERTAS, RIFAMPICINA 150 MG+ ISONIAZIDA 75 MG + PIRAZINAMIDA 400 MG+ ETAMBUTOL CLORHIDRATO 275 MG TABLETAS RECUBIERTASSynonyms: (+)-2,2'-(ethylenediimino)di-1-butanol, (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineDipyridamole
go.drugbank.com/drugs/DB00975ApprovedInvestigationalA phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 199...
Mixtures: AGGRENOX ® CAPSULAS DE LIBERACION RETARDADAProducts: DIPIRIDAMOL GRAGEAS DE 75 MG, DIPIRIDAMOL TABLETASUrsodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] Due to its hydrophilicity, UDCA is less toxic than [cholic acid] or [chenodeoxycholic acid]. … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.
Products: Urso DS, HEPARONEL® 600 MG TABLETASDinoprostone
go.drugbank.com/drugs/DB00917ApprovedInvestigationalDinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.
Synonyms: (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid, (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acidInternational brands: Prostarmon ESodium chloride
go.drugbank.com/drugs/DB09153ApprovedInvestigationalVet approvedSodium chloride is the primary salt in seawater and in the extracellular fluid of many multicellular organisms. It is listed on the World Health Organization Model List of Essential Medicines. … Sodium chloride, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions.
Mixtures: GLUCOSA AL 5% EN SOLUCION DE CLORURO DE SODIO AL 0.9%, INYECCION DE CLORURO DE POTASIO EN DEXTROSA AL 5% Y CLORURO DE SODIO 0.9% 20 MEQ/LProducts: CLORURO DE SODIO AL 0.9% EN AGUA INYECTABLE, CLORURO DE SODIO AL 0.9% EN AGUA INYECTABLE BAXTERAlfuzosin
go.drugbank.com/drugs/DB00346Approved[A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.
Categories: Drugs Used in Benign Prostatic HypertrophySynonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide